<DOC>
	<DOC>NCT02569242</DOC>
	<brief_summary>The purpose of study is to evaluate the efficacy and safety of Nivolumab in unresectable advanced or recurrent esophageal cancer patients who have failed in standard chemotherapies.</brief_summary>
	<brief_title>Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Men &amp; women â‰¥20 years of age Histologically confirmed unresectable advanced or recurrent esophageal cancer Refractory to or intolerant of standard therapy ECOG Performance Status score 0 or 1 A life expectancy of at least 3 months Current or past history of severe hypersensitivity to any other antibody products Patients with multiple primary cancers Patients with any metastasis in the brain or meninx that is symptomatic or requires treatment Patients with active, known or suspected autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>